More about
Her2-Negative Advanced Breast Cancer
News
December 08, 2023
2 min read
Save
Early progression on CDK4/6 regimen a ‘strong’ predictor of OS in breast cancer subset
SAN ANTONIO — The addition of either fulvestrant or letrozole to palbociclib conferred similar efficacy among patients with HER2-negative advanced breast cancer, according to data presented at San Antonio Breast Cancer Symposium.